IRIDEX (IRIDEX) EBIT

: $-10.01 Mil (TTM As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

IRIDEX's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-3.08 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.01 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. IRIDEX's annualized ROC % for the quarter that ended in Dec. 2023 was -58.09%. IRIDEX's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -124.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. IRIDEX's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -23.18%.

IRIDEX EBIT Historical Data

The historical data trend for IRIDEX's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-8.97

-6.58

-7.53

-7.54

-10.01

IRIDEX Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-1.41	-2.34	-2.89	-1.69	-3.08

Competitive Comparison

For the Medical Devices subindustry, IRIDEX's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRIDEX EV-to-EBIT Distribution

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IRIDEX's EV-to-EBIT falls into.

IRIDEX EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.01 Mil.

IRIDEX (NAS:IRIX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

IRIDEX's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-12.324 * ( 1 - -2.07% )	/	( (22.937	+	20.371)	/ 2 )
=	-12.5791068	/	21.654
=	-58.09 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	34.949	-	4.031	-	( 7.981	-	max(0, 10.348	-	27.342	+	7.981	))
=	22.937

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	34.436	-	7.031	-	( 7.034	-	max(0, 12.974	-	27.45	+	7.034	))
=	20.371

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

IRIDEX's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-12.324	/	( ( (3.313 + max(8.003, 0))	+	(2.983 + max(5.51, 0)) )	/	2 )
=	-12.324	/	( ( 11.316	+	8.493 )	/	2 )
=	-12.324	/	9.9045
=	-124.43 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6.109	+	10.118	+	1.129)	-	(4.031	+	2.239	+	3.083)
=	8.003

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6.727	+	9.906	+	0.856)	-	(7.031	+	3.329	+	1.619)
=	5.51

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

IRIDEX's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-10.007	/	43.170
	=	-23.18 %

IRIDEX EBIT Related Terms

Thank you for viewing the detailed overview of IRIDEX's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

IRIDEX (IRIDEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1212 Terra Bella Avenue, Mountain View, CA, USA, 94043

Website

https://www.iridex.com

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Executives

Nandini Devi	director	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss	director	C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove	director	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp	10 percent owner	75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp	10 percent owner	111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad	officer: Interim CFO	461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous	director	C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda	director	402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer	officer: COO	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz	director	C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne	director
Robert A Gunst	director
David Bruce	director, officer: President and CEO	1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum	director
Romeo R Dizon	other: Vice President and Controller	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043